Tag: Bayer

Bayer AG is a German multinational chemical, pharmaceutical and life sciences company. It is headquartered in Leverkusen, where its illuminated sign is a landmark. Bayer’s primary areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals and biotechnology products; and high value polymers.

Bayer received a warning letter from FDA

The German drugmaker, which is taking over U.S. seed maker Monsanto, is addressing the FDA’s complaints regarding manufacturing practices, which stem from a routine inspection in January.

Bayer aims to intensify its strategic pharmaceutical research

Bayer announced to further strengthen its strategic pharmaceutical research and development activities and bring them together under one leadership

Bayer and PeptiDream started a drug discovery collaboration

Bayer and PeptiDream have entered into a global drug discovery collaboration across multiple therapeutic areas and target classes

Loxo Oncology and Bayer sealed a drug development deal

cancer lab diagnostic
Loxo Oncology, Inc. announced that it has entered into a global collaboration with Bayer

Bayer and Compugen established a process development and service agreement

Compugen Ltd., has advanced COM902, its lead anti-TIGIT antibody, into manufacturing for an investigational new drug application anticipated in 2019

Primer Capital and Bayer become partners to support biotech startups

Primer Capital, a venture capital biotech fund, and Bayer have signed an agreement on the joint work to identify and develop the promising startups

Bayer and Ginkgo Bioworks will create new biotech company

Bayer and Ginkgo Bioworks will create a new company focused on the plant microbiome

Bayer will develop kidney diseases treatment along with Vanderbilt University

Vanderbilt University Medical Center and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases

Bayer recieved EU marketing authorization for Stivarga

Bayer announced the European Commission (EC) has granted marketing authorization for Stivarga® (regorafenib)

Bayer obtained FDA priority review for cancer drug

German drugmaker Bayer won the U.S. Food and Drug Administration's priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline.

Bayer got FDA approval for liver cancer drug

Bayer announced that the U.S. Food and Drug Administration (FDA) approved Stivarga® (regorafenib) tablets for the second-line treatment of patients with hepatocellular carcinoma (HCC) who have been pr...

Bayer is searching for business oportunities in China

German life science company Bayer AG regards China as a crucial market and is positively seeking business opportunities in areas including healthcare and agriculture, said Celina Chew, president of Ba...

Two Indian companies can export Bayer drugs for R&D

An Indian court granted a pair of drugmakers the right to export the main ingredients of two of Bayer AG’s top-selling drugs to develop generics in other countries, a decision that has the potential t...

Bayer posts 7.3% rise in sales of prescription drugs in the fourth quarter of 2016

Bayer announced that fourth-quarter sales of prescription drugs rose 7.3 percent year-over-year to 4.3 billion euros ($4.5 billion), with revenue from key growth products including Eylea and Xarelto i...